Evidence map›Paper›PMID 32611637›Full record

Observational studyNeurology2020

Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers.

Edmarie Guzmán-Vélez, Jairo Martínez, Kate Papp, Ana Baena, Clara Vila-Castelar, Arabiye Artola, Aaron P Schultz, Yamile Bocanegra, Justin Sanchez, Dorene Rentz and 6 more

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Genetic modifiers of cognitive decline in PSEN1 E280A Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  2. Review
  3. Review
  4. Associations of category fluency clustering performance withJournal of the International Neuropsychological Society : JINS · 2024
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 2 countries.

Edmarie Guzmán-VélezFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Jairo MartínezFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Kate PappFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Ana BaenaFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Clara Vila-CastelarFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Arabiye ArtolaFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Aaron P SchultzFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Yamile BocanegraFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Justin SanchezFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.ORCID 0000-0003-4421-3078
Dorene RentzFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.ORCID 0000-0002-6318-9213
Pierre N TariotFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.ORCID 0000-0002-6058-8032
Eric M ReimanFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.ORCID 0000-0002-0705-3696
Reisa SperlingFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Keith A JohnsonFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Francisco LoperaFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ.
Yakeel T QuirozFrom the Departments of Psychiatry (E.G.V., J.M., C.V.-C., A.A., J.S., Y.T.Q.), Neurology (A.P.S., D.R., R.S., K.A.J., Y.T.Q.), and Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Grupo de Neurociencias (A.B., Y.B., F.L., Y.T.Q.), Universidad de Antioquia, Medellín, Colombia; Center for Alzheimer Research and Treatment (K.P., D.R., R.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; and Banner Alzheimer's Institute (P.N.T., E.M.R.), Phoenix, AZ. yquiroz@mgh.harvard.edu.ORCID 0000-0001-9714-8244
Alzheimer's Association · US

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Teresa Gomez-Isla · 2019 to 2026
$36.5M
Alzheimer's Prevention Initiative ADAD Colombia TrialR01AG055444 · NIA · BANNER HEALTH · PI LOPERA, FRANCISCO, REIMAN, ERIC MICHAEL · 2017 to 2022
$14.9M
Relationship between tau pathology and cognitive impairment in autosomal dominant Alzheimer's diseaseR01AG054671 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2017 to 2021
$3.8M
Memory network dysfunction as an early marker of preclinical Alzheimer's DiseaseDP5OD019833 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2014 to 2018
$2.3M
Aerobic fitness as a modifier of neurodegeneration and cognitive decline in preclinical Alzheimer's diseaseK23AG061276 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GUZMÁN-VÉLEZ, EDMARIE · 2019 to 2023
$881k
NIA NIH HHS K23 AG061276NIA NIH HHS P30 AG062421NIA NIH HHS R01 AG054671NIA NIH HHS R01 AG055444NIH HHS DP5 OD019833
6 · The paper itself

Abstract

objectiveTo determine whether performance on the Free and Cued Selective Reminding Test (FCSRT) is associated with PET in vivo markers of brain pathology and whether it can distinguish those who will develop dementia later in life due to autosomal-dominant Alzheimer disease (AD) from age-matched controls.

methodsTwenty-four cognitively unimpaired Presenilin-1 E280A carriers (mean age 36 years) and 28 noncarriers (mean age 37 years) underwent Pittsburg compound B-PET (amyloid), flortaucipir-PET (tau), and cognitive testing, including the FCSRT (immediate and delayed free and cued recall scores). Linear regressions were used to examine the relationships among FCSRT scores, age, mean cortical amyloid, and regional tau burden.

resultsFree and total recall scores did not differ between cognitively unimpaired mutation carriers and noncarriers. Greater age predicted lower free recall and delayed free and total recall scores in carriers. In cognitively impaired carriers, delayed free recall predicted greater amyloid burden and entorhinal tau, while worse immediate free recall scores predicted greater tau in the inferior temporal and entorhinal cortices. In turn, in all carriers, lower free and total recall scores predicted greater amyloid and regional tau pathology.

conclusionsFCSRT scores were associated with in vivo markers of AD-related pathology in cognitively unimpaired individuals genetically determined to develop dementia. Difficulties on free recall, particularly delayed recall, were evident earlier in the disease trajectory, while difficulties on cued recall were seen only as carriers neared the onset of dementia, consistent with the pathologic progression of the disease. Findings suggest that the FCSRT can be a useful measure to track disease progression in AD.

Indexed as

Mental RecallAdultAlzheimer DiseaseBrainFemaleGenetic Predisposition to DiseaseHeterozygoteHumansLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission TomographyPresenilin-1Young AdultPresenilin-1PSEN1 protein, human

Identifiers

PMID32611637
PMCPMC7538214
OpenAlexW3039209272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.